aTyr Pharma investors sue over alleged misleading statements and drug efficacy claims.

Thursday, Nov 6, 2025 8:30 am ET1min read
ATYR--

A class action lawsuit has been filed against aTyr Pharma for violating the Securities Exchange Act of 1934. The lawsuit alleges that the company made false and misleading statements about the efficacy of its drug candidate, Efzofitimod, and its potential to help patients taper steroid usage. Shareholders who purchased shares during the class period (January 16, 2025 to September 12, 2025) are encouraged to contact the firm regarding possible lead plaintiff appointments. The deadline to join the lawsuit is December 8, 2025.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet